BioAge Labs Stock

BioAge Labs is a clinical-stage biotechnology company that develops therapeutics to treat obesity and metabolic diseases.

Sign up today and learn more about BioAge Labs Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About BioAge Labs Stock

BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with tirzepatide to potentially become a groundbreaking treatment for obesity in the elderly.

Funding History

July 2017$10.9M
January 2019$23.0M
December 2020$90.0M
February 2024$170M

Management

CEO & Co-Founder

Kristen Fortney

Co-founder and COO

Eric Morgen

Chief Business Officer

Peng Leong

Investor

Ling Wong

Consultant for Chemistry & Strategy

George Hartman

Board Of Director

Vijay Pande

Board of Directors

Eric Morgen

Board Member

Medha Agarwal

VP, Program Management

Robert Hopkins

Board Observer

Joe Betts-Lacroix

Chief Financial Officer

Dov Goldstein

SVP Translational Aging Biology

Justin Rebo

Board Director

Patrick Enright

Chairman of the Board

James Healy

Independent Director

Donald J. Santel

Board of Directors

Kristen Fortney

CMO

Paul Rubin

Chief Development Officer

Ann Neale

Board Member

Rekha Hemrajani

SVP, Venture Head, Apelin Muscle Aging Program

Carrie-Lynn Langlais Furr

VP Biochemistry

Robert Hughes

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo